Table 1. Summary of baseline demographic variables and relevant comorbidities and medications for all patients with follow-up.
| Baseline valuesa |
All subjects (n=180) |
Stroke recurrence (n=20) |
No recurrence (n=160) |
P valueb | |||||
|---|---|---|---|---|---|---|---|---|---|
| Min | Max | Mean | s.d. | Mean | s.d. | Mean | s.d. | ||
| Age (years) | 34 | 95 | 65.8 | 11.6 | 67.9 | 13.8 | 65.5 | 11.3 | 0.69 |
| NIHSS | 2 | 38 | 12.7 | 8.4 | 9.7 | 6.4 | 13.1 | 8.6 | 0.20 |
| Count (%) |
Count (%) |
Count (%) |
|||||||
| Male | 134 (74%) | 13 (65%) | 121 (76%) | 0.21 | |||||
| Race/ethnicity | 0.83 | ||||||||
| Caucasian | 127 (71%) | 14 (70%) | 113 (71%) | ||||||
| African American | 50 (28%) | 6 (30%) | 44 (28%) | ||||||
| Hispanic | 1 (<1%) | 0 | 1 (<1%) | ||||||
| American Indian | 1 (<1%) | 0 | 1 (<1%) | ||||||
| Other | 1 (<1%) | 0 | 1 (<1%) | ||||||
| Smokers | 85 (47%) | 8 (40%) | 77 (48%) | 0.39 | |||||
| Antiplatelet use | 103 (57%) | 13 (65%) | 90 (56%) | 0.60 | |||||
| SSRI use | 14 (8%) | 0 | 14 (9%) | 0.20 | |||||
| Statin use | 70 (39%) | 10 (50%) | 60 (38%) | 0.33 | |||||
| Diabetes | 59 (33%) | 6 (30%) | 53 (33%) | 0.81 | |||||
| End stage renal disease | 7 (4%) | 0 | 7 (4%) | 0.41 | |||||
| Atrial fibrillation | 30 (17%) | 3 (15%) | 27 (17%) | 0.86 | |||||
| Hypertension | 135 (75%) | 15 (75%) | 120 (75%) | 0.99 | |||||
| Hypercholesterolemia | 85 (47%) | 10 (50%) | 75 (47%) | 0.90 | |||||
| Large artery disease | 55 (31%) | 10 (50%) | 45 (28%) | 0.040 | |||||
NIHSS, National Institutes of Health Stroke Scale; SSRI, selective serotonin reuptake inhibitors.
a
Data are summarized using the minimum (Min), maximum (Max), mean and s.d., or count (%).
b
P value comparing the time-to-recurrence distribution between groups defined by the indicated characteristic at baseline using the log-rank test. Age comparison is between groups above and below the median (64 years) and race/ethnicity comparison is between Caucasians and all others.